Next-Generation In-vitro Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Core Laboratory Diagnostics, PoC Testing, Molecular Diagnostics, Others), By Product (Consumables, Instruments, Software), By Application (Oncology/Cancer, Infectious Diseases, Diabetes, Cardiology, Others), By End User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutions, Others), By Region and Competition, 2019-2029F
Global Next-Generation In-vitr%lI%Diagnostics Market was valued at USD 84.74 Billion in 2023 and is anticipated t%lI%project steady growth in the forecast period with a CAGR of 8.21% through 2029. IVDs, or Next-Generation In-Vitr%lI%Diagnostics, are cutting-edge and innovative diagnostic technologies that are used for non-invasive diagnostic testing. These advanced diagnostic tools are a major development in the field of diagnostics, providing improved precision, effectiveness, and dependability in the detection and monitoring of a variety of diseases and conditions. The growth is further augmented by increasing investment and development t%lI%innovate products and explore new applications of next generation IVD techniques. The industrial implications for the development of emerging economies in developing countries, are significant for the next generation in vitr%lI%diagnostics market. These regions are facing a growing demand for better healthcare systems, better access t%lI%quality diagnostics and the adoption of cutting-edge technologies t%lI%treat diseases. The regulatory landscape and reimbursement policies play a significant role in the development and uptake of next generation IVD technologies around the world. Providing favorable regulations and reimbursement structures that enable the smooth integration of IVD technologies int%lI%the standard of care can significantly increase market growth.
Key Market Drivers
Technological Advancements in Next-Generation In-vitr%lI%Diagnostics
IVD has undergone a significant transformation due t%lI%the development of cutting-edge technologies, such as genomics, proteomics, and molecular diagnostic techniques. These advances, including NGS (Next Generation Sequencing), digital PCR (PCR), and other pioneering technologies, have significantly improved the accuracy, sensitivity, and effectiveness of diagnostic testing. Molecular diagnostic techniques were becoming progressively advanced, enabling the detection of DNA and RNA for the purpose of diagnosing infections, genetic diseases, and various malignancies. NGS (Next Generation Sequencing) technology has revolutionized the field of genetic testing, allowing for rapid and accurate sequencing of both DNA and RNA. This technology has enabled the analysis of intricate genetic variations, as well as providing valuable information for the development of personalized medicine and the profiling of cancer. The utilization of IVD technologies, such as Wearable Devices (WFDs) and Home Testing Kits (HTKs), allows for the remote monitoring of patient health conditions. This allows for the continuous monitoring of chronic conditions and facilitates the remote management of disease. Patients can monitor their health parameters and transfer data t%lI%healthcare providers t%lI%initiate timely interventions and modify treatment plans. Liquid biopsy techniques have advanced t%lI%the point where they can be used t%lI%detect circulating tumor cells in blood samples without the need for an invasive procedure, as well as other biomarkers that can provide valuable information for the diagnosis and monitoring of cancer. Biosensors and nanotechnologies have enabled the development of diagnostic tools that are highly sensitive and precise, allowing for the early detection and quantification of biomarkers. Improvements in data interchangeability and connectivity standards enabled IVD devices t%lI%be seamlessly integrated int%lI%healthcare information systems, thereby improving data interchange and patient care coordination. T%lI%sum up, in vitr%lI%diagnostics is revolutionizing the healthcare system by increasing precision and accuracy, early detection, personalized medicine, remote and point of care testing, data driven healthcare, streamlining workflow, remote monitoring, and disease management. These innovations have the potential t%lI%improve patient outcomes, improve resource efficiency, and revolutionize healthcare delivery. This factor will pace up the demand of Global Next Generation In-vitr%lI%Diagnostics Market.
Rising Demand of Point-of-Care Testing
POCT (point-of-care testing) is an essential element of IVD diagnostics. POCT refers t%lI%diagnostic tests conducted at or near the patient's point of care, such as a physician's office, a clinic, or the patient's bedside, as opposed t%lI%samples being sent t%lI%a laboratory for analysis. POCT offers several advantages, one of which is its ability t%lI%provide results in real-time, often in as little as a few minutes. This expedited response allows healthcare professionals t%lI%make timely treatment decisions and enhance patient care. With fast and local testing, POCT makes it easier t%lI%spot and diagnose illnesses early, s%lI%you can get treatment as soon as possible and see better results for your patients. POCT allows healthcare professionals t%lI%always keep an eye on patient’s health, which makes it especially useful for chronic disease treatment and therapeutic monitoring. POCT eliminates the need t%lI%send samples t%lI%a remote laboratory and wait for the results, thus reducing the likelihood of sample degradation and diagnostic delays. POCT devices are typically easy t%lI%use and require minimal instruction, making the testing process easier for healthcare professionals. POCT devices may incur higher initial out-of-pocket expenses, however, the overall cost effectiveness of such tests can be considerable, particularly when considering the reduction of hospital stays and improved use of resources. POCT can be useful in cases like an outbreak of an infectious disease, as it can help quickly identify wh%lI%is at risk and put in place the right measures t%lI%keep them safe. This factor will accelerate the demand of Global Next Generation In-vitr%lI%Diagnostics Market.
Growing Prevalence of Chronic Diseases
Chronic diseases have been on the rise for the past several decades and remain a major global health issue. These chronic conditions, als%lI%referred t%lI%as NCDs (non-communicable diseases), are characterized by a slow progression of symptoms and are usually caused by complex underlying conditions. Common types of NCDs include cardiovascular disease (heart disease, stroke, diabetes, cancer), chronic respiratory disease (such as COPD) and obesity. According t%lI%American Cancer Society, around 19.3 million people were diagnosed with cancer in 2020, and nearly 10.0 million people died of it around the World. Breast cancer is now the most common type of cancer, with over 2.3 million people diagnosed each year. Lung cancer is second with 11.7%, followed by colorectal with 10.0%, prostate with 7.3%, and stomach with 5.6%. Chronic diseases are caused by a variety of factors, but the most common are poor diet, poor physical activity, tobacc%lI%consumption, and excessive consumption of alcohol. Unfortunately, these lifestyle choices are common in many countries and contribute t%lI%the onset of chronic diseases such as obesity, diabetes, and cardiovascular disease. Urbanization has been associated with a decrease in physical activity and an increase in reliance on motorized transportation, both of which have been linked t%lI%an increased risk of chronic diseases. Chronic diseases can be caused by a variety of environmental factors, including atmospheric pollution, exposure t%lI%toxic substances, and certain workplace risks. Certain chronic diseases may be caused by genetic factors, and those with a familial history of certain diseases may be more susceptible t%lI%developing them. This factor will help in the growth of Global Next-Generation In-vitr%lI%Diagnostics Market.
Demand for Early & Accurate Disease Diagnosis
The demand for early and accurate disease diagnosis is driving an increase in the global demand for next-generation in-vitr%lI%diagnostics (IVD). Timely and precise diagnosis is crucial for effective disease management, enabling healthcare providers t%lI%initiate appropriate treatments promptly and monitor patient response. Next-generation IVD technologies offer significant advancements over traditional diagnostic methods, providing greater sensitivity, specificity, and speed in detecting a wide range of diseases and conditions. These innovative diagnostics encompass various platforms, including molecular diagnostics, immunoassays, and point-of-care testing, each offering unique advantages in terms of versatility, automation, and portability. Next-generation IVDs facilitate the detection of biomarkers and genetic markers associated with specific diseases, enabling personalized and targeted therapies. As healthcare systems worldwide increasingly prioritize early disease detection and intervention t%lI%improve patient outcomes and reduce healthcare costs, the demand for next-generation IVDs continues t%lI%grow. Pharmaceutical companies, diagnostic manufacturers, and research institutions are investing in the development of innovative diagnostic technologies t%lI%meet this demand, driving market expansion and technological innovation in the field of in-vitr%lI%diagnostics. The rising demand for early and accurate disease diagnosis underscores the critical role of next-generation IVDs in advancing healthcare delivery and improving patient care globally.
Key Market Challenges
High Development Costs
The high development costs associated with next-generation in-vitr%lI%diagnostics (IVD) are contributing t%lI%a decrease in demand globally. Developing innovative diagnostic technologies requires substantial investment in research, development, regulatory approval, and commercialization. The complex nature of next-generation IVD platforms, coupled with stringent regulatory requirements and the need for extensive clinical validation, results in significant upfront costs and prolonged development timelines. These high development costs pose a barrier t%lI%entry for smaller companies and startups, limiting the diversity of players in the market and constraining competition. The high cost of next-generation IVD technologies may deter healthcare providers and institutions from adopting these advanced diagnostics, particularly in resource-limited settings where budget constraints are more pronounced. Consequently, the limited accessibility and affordability of next-generation IVD platforms hinder their widespread adoption and utilization, diminishing overall demand. Despite their potential t%lI%improve patient outcomes and healthcare delivery, the high development costs associated with next-generation IVD technologies present a challenge t%lI%market growth and innovation in the field. Addressing these cost barriers through collaborative funding initiatives, streamlined regulatory pathways, and innovative financing models is essential t%lI%stimulate demand and drive the advancement of next-generation in-vitr%lI%diagnostics on a global scale.
Complexity of Integration
The complexity of integration poses a significant challenge t%lI%the widespread adoption of next-generation in-vitr%lI%diagnostics (IVD) globally, thereby decreasing demand. Next-generation IVD technologies often involve intricate systems and platforms that require seamless integration with existing healthcare infrastructures, including laboratory information systems (LIS), electronic health records (EHR), and hospital networks. However, the integration process can be complex and time-consuming, involving compatibility issues, data interoperability challenges, and customization requirements tailored t%lI%specific healthcare settings. The deployment of next-generation IVD systems may necessitate extensive training for healthcare personnel t%lI%effectively operate and interpret results, further adding t%lI%the complexity of implementation. These integration challenges present barriers t%lI%adoption for healthcare providers, particularly in resource-constrained settings where infrastructure and technical expertise may be limited. Consequently, the perceived complexity of integration hinders the uptake of next-generation IVD technologies, diminishing demand globally. Addressing these integration challenges requires collaborative efforts between technology developers, healthcare providers, and regulatory agencies t%lI%streamline interoperability standards, enhance user-friendly interfaces, and provide comprehensive training and support. By mitigating the complexity of integration, stakeholders can accelerate the adoption of next-generation in-vitr%lI%diagnostics, unlocking their full potential t%lI%improve patient care and healthcare delivery worldwide.
Key Market Trends
The global increase in healthcare expenditure is significantly boosting the demand for next-generation in-vitr%lI%diagnostics (IVD) technologies. As healthcare systems worldwide allocate more resources t%lI%improve patient care and enhance healthcare outcomes, there is a growing recognition of the critical role that advanced diagnostics play in achieving these objectives. Next-generation IVD technologies offer several advantages over traditional diagnostic methods, including greater accuracy, speed, and efficiency in detecting diseases and guiding treatment decisions. These innovations empower healthcare providers t%lI%deliver more personalized and targeted care, optimizing patient outcomes while minimizing healthcare costs associated with misdiagnosis, ineffective treatments, and prolonged hospital stays. The rising prevalence of chronic diseases, aging populations, and infectious outbreaks underscores the need for robust diagnostic solutions capable of rapidly and accurately identifying a diverse range of medical conditions. Consequently, healthcare stakeholders are increasingly investing in next-generation IVD platforms, driving market growth and technological innovation in the field. Pharmaceutical companies, diagnostic manufacturers, and research institutions are collaborating t%lI%develop novel diagnostic assays, platforms, and technologies t%lI%meet the growing demand for advanced diagnostic solutions. Overall, the surge in healthcare expenditure globally is fueling the demand for next-generation in-vitr%lI%diagnostics, reshaping healthcare delivery and paving the way for more effective and efficient patient care.
Strategic Collaborations & Mergers Within the Industry
The increase in strategic collaborations and mergers within the healthcare industry is playing a significant role in driving up the demand for next-generation in-vitr%lI%diagnostics (IVD) globally. Collaborations between pharmaceutical companies, diagnostic manufacturers, research institutions, and technology firms are fostering synergies that accelerate innovation and drive the development of advanced diagnostic solutions. These partnerships enable the pooling of resources, expertise, and technology platforms, facilitating the rapid development and commercialization of next-generation IVD technologies. Strategic mergers and acquisitions within the industry are leading t%lI%the consolidation of key players, creating economies of scale and enhancing market reach. As a result, companies are better positioned t%lI%invest in research and development, expand their product portfolios, and address emerging market needs. Strategic collaborations and mergers enable companies t%lI%leverage complementary capabilities and access new markets, driving market growth and increasing the adoption of next-generation IVD technologies worldwide. The trend towards increased collaboration and consolidation within the healthcare industry is fueling demand for advanced diagnostic solutions, reshaping the landscape of in-vitr%lI%diagnostics, and driving innovation t%lI%address unmet medical needs globally.
Segmental Insights
Type Insights
Based on Type, Molecular Diagnostics have emerged as fastest growing segment in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. With its high sensitivity and accuracy, coupled with the ability t%lI%detect and quantify multiple diseases, molecular diagnostics are revolutionizing personalized medicine and transforming the way we manage a plethora of health conditions. This segment's dominance is driven by continuous technological advancements, which have further enhanced the capabilities of these diagnostic tools. The increased prevalence of infectious and chronic diseases has amplified the need for accurate and timely disease detection. The growing demand for precision medicine, which focuses on tailoring medical treatments based on an individual's unique genetic makeup, has further propelled the adoption of molecular diagnostics. As a result, this innovative approach t%lI%diagnostics is paving the way for more targeted and effective healthcare interventions, ultimately improving patient outcomes and quality of life.
Product Insights
Based on Product, Consumables have emerged as the dominating segment in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. This dominance can be attributed t%lI%the recurring and indispensable need for various disposables, such as reagents, test strips, and other assay kits, that are integral t%lI%IVD procedures. The demand for consumables is sustained by the high volume of routine testing performed in healthcare settings, as well as the continuous emergence of new test reagents and the necessity t%lI%maintain an adequate stock for potential disease outbreaks.
Regional Insights
Based on Region, North America have emerged as the dominating region in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. This can be attributed t%lI%several key factors. The region boasts a robust and advanced healthcare infrastructure, facilitating the seamless adoption and integration of innovative diagnostic technologies. North America is home t%lI%key market players wh%lI%are at the forefront of driving advancements in diagnostics. These players bring extensive expertise and resources t%lI%propel the market forward. Ongoing investments in research and development within the biotechnology and healthcare sectors further contribute t%lI%the region's leadership in next-generation in-vitr%lI%diagnostics. There is a growing patient awareness about the benefits of early diagnosis and personalized medicine, which is fueling the demand for advanced diagnostic solutions in this region. Collectively, these factors position North America as a frontrunner in the global market, setting the stage for continued growth and advancements in next-generation in-vitr%lI%diagnostics.
Key Market Players
In this report, the Global Next-Generation In-vitr%lI%Diagnostics Market has been segmented int%lI%the following categories, in addition t%lI%the industry trends which have als%lI%been detailed below:
%lI%POC Testing
%lI%Molecular Diagnostics
%lI%Others
%lI%Instruments
%lI%Software
%lI%Infectious Diseases
%lI%Diabetes
%lI%Cardiology
%lI%Others
%lI%Diagnostic Laboratories
%lI%Academic And Research Institutions
%lI%Others
%lI%United States
%lI%Canada
%lI%Mexico
%lI%Europe
%lI%France
%lI%United Kingdom
%lI%Italy
%lI%Germany
%lI%Spain
%lI%Asia Pacific
%lI%China
%lI%India
%lI%Japan
%lI%Australia
%lI%South Korea
%lI%South America
%lI%Brazil
%lI%Argentina
%lI%Colombia
%lI%Middle East & Africa
%lI%South Africa
%lI%Saudi Arabia
%lI%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation In-vitr%lI%Diagnostics Market.
Available Customizations:
Global Next-Generation In-vitr%lI%Diagnostics Market report with the given market data, TechSci Research offers customizations according t%lI%a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Technological Advancements in Next-Generation In-vitr%lI%Diagnostics
IVD has undergone a significant transformation due t%lI%the development of cutting-edge technologies, such as genomics, proteomics, and molecular diagnostic techniques. These advances, including NGS (Next Generation Sequencing), digital PCR (PCR), and other pioneering technologies, have significantly improved the accuracy, sensitivity, and effectiveness of diagnostic testing. Molecular diagnostic techniques were becoming progressively advanced, enabling the detection of DNA and RNA for the purpose of diagnosing infections, genetic diseases, and various malignancies. NGS (Next Generation Sequencing) technology has revolutionized the field of genetic testing, allowing for rapid and accurate sequencing of both DNA and RNA. This technology has enabled the analysis of intricate genetic variations, as well as providing valuable information for the development of personalized medicine and the profiling of cancer. The utilization of IVD technologies, such as Wearable Devices (WFDs) and Home Testing Kits (HTKs), allows for the remote monitoring of patient health conditions. This allows for the continuous monitoring of chronic conditions and facilitates the remote management of disease. Patients can monitor their health parameters and transfer data t%lI%healthcare providers t%lI%initiate timely interventions and modify treatment plans. Liquid biopsy techniques have advanced t%lI%the point where they can be used t%lI%detect circulating tumor cells in blood samples without the need for an invasive procedure, as well as other biomarkers that can provide valuable information for the diagnosis and monitoring of cancer. Biosensors and nanotechnologies have enabled the development of diagnostic tools that are highly sensitive and precise, allowing for the early detection and quantification of biomarkers. Improvements in data interchangeability and connectivity standards enabled IVD devices t%lI%be seamlessly integrated int%lI%healthcare information systems, thereby improving data interchange and patient care coordination. T%lI%sum up, in vitr%lI%diagnostics is revolutionizing the healthcare system by increasing precision and accuracy, early detection, personalized medicine, remote and point of care testing, data driven healthcare, streamlining workflow, remote monitoring, and disease management. These innovations have the potential t%lI%improve patient outcomes, improve resource efficiency, and revolutionize healthcare delivery. This factor will pace up the demand of Global Next Generation In-vitr%lI%Diagnostics Market.
Rising Demand of Point-of-Care Testing
POCT (point-of-care testing) is an essential element of IVD diagnostics. POCT refers t%lI%diagnostic tests conducted at or near the patient's point of care, such as a physician's office, a clinic, or the patient's bedside, as opposed t%lI%samples being sent t%lI%a laboratory for analysis. POCT offers several advantages, one of which is its ability t%lI%provide results in real-time, often in as little as a few minutes. This expedited response allows healthcare professionals t%lI%make timely treatment decisions and enhance patient care. With fast and local testing, POCT makes it easier t%lI%spot and diagnose illnesses early, s%lI%you can get treatment as soon as possible and see better results for your patients. POCT allows healthcare professionals t%lI%always keep an eye on patient’s health, which makes it especially useful for chronic disease treatment and therapeutic monitoring. POCT eliminates the need t%lI%send samples t%lI%a remote laboratory and wait for the results, thus reducing the likelihood of sample degradation and diagnostic delays. POCT devices are typically easy t%lI%use and require minimal instruction, making the testing process easier for healthcare professionals. POCT devices may incur higher initial out-of-pocket expenses, however, the overall cost effectiveness of such tests can be considerable, particularly when considering the reduction of hospital stays and improved use of resources. POCT can be useful in cases like an outbreak of an infectious disease, as it can help quickly identify wh%lI%is at risk and put in place the right measures t%lI%keep them safe. This factor will accelerate the demand of Global Next Generation In-vitr%lI%Diagnostics Market.
Growing Prevalence of Chronic Diseases
Chronic diseases have been on the rise for the past several decades and remain a major global health issue. These chronic conditions, als%lI%referred t%lI%as NCDs (non-communicable diseases), are characterized by a slow progression of symptoms and are usually caused by complex underlying conditions. Common types of NCDs include cardiovascular disease (heart disease, stroke, diabetes, cancer), chronic respiratory disease (such as COPD) and obesity. According t%lI%American Cancer Society, around 19.3 million people were diagnosed with cancer in 2020, and nearly 10.0 million people died of it around the World. Breast cancer is now the most common type of cancer, with over 2.3 million people diagnosed each year. Lung cancer is second with 11.7%, followed by colorectal with 10.0%, prostate with 7.3%, and stomach with 5.6%. Chronic diseases are caused by a variety of factors, but the most common are poor diet, poor physical activity, tobacc%lI%consumption, and excessive consumption of alcohol. Unfortunately, these lifestyle choices are common in many countries and contribute t%lI%the onset of chronic diseases such as obesity, diabetes, and cardiovascular disease. Urbanization has been associated with a decrease in physical activity and an increase in reliance on motorized transportation, both of which have been linked t%lI%an increased risk of chronic diseases. Chronic diseases can be caused by a variety of environmental factors, including atmospheric pollution, exposure t%lI%toxic substances, and certain workplace risks. Certain chronic diseases may be caused by genetic factors, and those with a familial history of certain diseases may be more susceptible t%lI%developing them. This factor will help in the growth of Global Next-Generation In-vitr%lI%Diagnostics Market.
Demand for Early & Accurate Disease Diagnosis
The demand for early and accurate disease diagnosis is driving an increase in the global demand for next-generation in-vitr%lI%diagnostics (IVD). Timely and precise diagnosis is crucial for effective disease management, enabling healthcare providers t%lI%initiate appropriate treatments promptly and monitor patient response. Next-generation IVD technologies offer significant advancements over traditional diagnostic methods, providing greater sensitivity, specificity, and speed in detecting a wide range of diseases and conditions. These innovative diagnostics encompass various platforms, including molecular diagnostics, immunoassays, and point-of-care testing, each offering unique advantages in terms of versatility, automation, and portability. Next-generation IVDs facilitate the detection of biomarkers and genetic markers associated with specific diseases, enabling personalized and targeted therapies. As healthcare systems worldwide increasingly prioritize early disease detection and intervention t%lI%improve patient outcomes and reduce healthcare costs, the demand for next-generation IVDs continues t%lI%grow. Pharmaceutical companies, diagnostic manufacturers, and research institutions are investing in the development of innovative diagnostic technologies t%lI%meet this demand, driving market expansion and technological innovation in the field of in-vitr%lI%diagnostics. The rising demand for early and accurate disease diagnosis underscores the critical role of next-generation IVDs in advancing healthcare delivery and improving patient care globally.
Key Market Challenges
High Development Costs
The high development costs associated with next-generation in-vitr%lI%diagnostics (IVD) are contributing t%lI%a decrease in demand globally. Developing innovative diagnostic technologies requires substantial investment in research, development, regulatory approval, and commercialization. The complex nature of next-generation IVD platforms, coupled with stringent regulatory requirements and the need for extensive clinical validation, results in significant upfront costs and prolonged development timelines. These high development costs pose a barrier t%lI%entry for smaller companies and startups, limiting the diversity of players in the market and constraining competition. The high cost of next-generation IVD technologies may deter healthcare providers and institutions from adopting these advanced diagnostics, particularly in resource-limited settings where budget constraints are more pronounced. Consequently, the limited accessibility and affordability of next-generation IVD platforms hinder their widespread adoption and utilization, diminishing overall demand. Despite their potential t%lI%improve patient outcomes and healthcare delivery, the high development costs associated with next-generation IVD technologies present a challenge t%lI%market growth and innovation in the field. Addressing these cost barriers through collaborative funding initiatives, streamlined regulatory pathways, and innovative financing models is essential t%lI%stimulate demand and drive the advancement of next-generation in-vitr%lI%diagnostics on a global scale.
Complexity of Integration
The complexity of integration poses a significant challenge t%lI%the widespread adoption of next-generation in-vitr%lI%diagnostics (IVD) globally, thereby decreasing demand. Next-generation IVD technologies often involve intricate systems and platforms that require seamless integration with existing healthcare infrastructures, including laboratory information systems (LIS), electronic health records (EHR), and hospital networks. However, the integration process can be complex and time-consuming, involving compatibility issues, data interoperability challenges, and customization requirements tailored t%lI%specific healthcare settings. The deployment of next-generation IVD systems may necessitate extensive training for healthcare personnel t%lI%effectively operate and interpret results, further adding t%lI%the complexity of implementation. These integration challenges present barriers t%lI%adoption for healthcare providers, particularly in resource-constrained settings where infrastructure and technical expertise may be limited. Consequently, the perceived complexity of integration hinders the uptake of next-generation IVD technologies, diminishing demand globally. Addressing these integration challenges requires collaborative efforts between technology developers, healthcare providers, and regulatory agencies t%lI%streamline interoperability standards, enhance user-friendly interfaces, and provide comprehensive training and support. By mitigating the complexity of integration, stakeholders can accelerate the adoption of next-generation in-vitr%lI%diagnostics, unlocking their full potential t%lI%improve patient care and healthcare delivery worldwide.
Key Market Trends
The global increase in healthcare expenditure is significantly boosting the demand for next-generation in-vitr%lI%diagnostics (IVD) technologies. As healthcare systems worldwide allocate more resources t%lI%improve patient care and enhance healthcare outcomes, there is a growing recognition of the critical role that advanced diagnostics play in achieving these objectives. Next-generation IVD technologies offer several advantages over traditional diagnostic methods, including greater accuracy, speed, and efficiency in detecting diseases and guiding treatment decisions. These innovations empower healthcare providers t%lI%deliver more personalized and targeted care, optimizing patient outcomes while minimizing healthcare costs associated with misdiagnosis, ineffective treatments, and prolonged hospital stays. The rising prevalence of chronic diseases, aging populations, and infectious outbreaks underscores the need for robust diagnostic solutions capable of rapidly and accurately identifying a diverse range of medical conditions. Consequently, healthcare stakeholders are increasingly investing in next-generation IVD platforms, driving market growth and technological innovation in the field. Pharmaceutical companies, diagnostic manufacturers, and research institutions are collaborating t%lI%develop novel diagnostic assays, platforms, and technologies t%lI%meet the growing demand for advanced diagnostic solutions. Overall, the surge in healthcare expenditure globally is fueling the demand for next-generation in-vitr%lI%diagnostics, reshaping healthcare delivery and paving the way for more effective and efficient patient care.
Strategic Collaborations & Mergers Within the Industry
The increase in strategic collaborations and mergers within the healthcare industry is playing a significant role in driving up the demand for next-generation in-vitr%lI%diagnostics (IVD) globally. Collaborations between pharmaceutical companies, diagnostic manufacturers, research institutions, and technology firms are fostering synergies that accelerate innovation and drive the development of advanced diagnostic solutions. These partnerships enable the pooling of resources, expertise, and technology platforms, facilitating the rapid development and commercialization of next-generation IVD technologies. Strategic mergers and acquisitions within the industry are leading t%lI%the consolidation of key players, creating economies of scale and enhancing market reach. As a result, companies are better positioned t%lI%invest in research and development, expand their product portfolios, and address emerging market needs. Strategic collaborations and mergers enable companies t%lI%leverage complementary capabilities and access new markets, driving market growth and increasing the adoption of next-generation IVD technologies worldwide. The trend towards increased collaboration and consolidation within the healthcare industry is fueling demand for advanced diagnostic solutions, reshaping the landscape of in-vitr%lI%diagnostics, and driving innovation t%lI%address unmet medical needs globally.
Segmental Insights
Type Insights
Based on Type, Molecular Diagnostics have emerged as fastest growing segment in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. With its high sensitivity and accuracy, coupled with the ability t%lI%detect and quantify multiple diseases, molecular diagnostics are revolutionizing personalized medicine and transforming the way we manage a plethora of health conditions. This segment's dominance is driven by continuous technological advancements, which have further enhanced the capabilities of these diagnostic tools. The increased prevalence of infectious and chronic diseases has amplified the need for accurate and timely disease detection. The growing demand for precision medicine, which focuses on tailoring medical treatments based on an individual's unique genetic makeup, has further propelled the adoption of molecular diagnostics. As a result, this innovative approach t%lI%diagnostics is paving the way for more targeted and effective healthcare interventions, ultimately improving patient outcomes and quality of life.
Product Insights
Based on Product, Consumables have emerged as the dominating segment in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. This dominance can be attributed t%lI%the recurring and indispensable need for various disposables, such as reagents, test strips, and other assay kits, that are integral t%lI%IVD procedures. The demand for consumables is sustained by the high volume of routine testing performed in healthcare settings, as well as the continuous emergence of new test reagents and the necessity t%lI%maintain an adequate stock for potential disease outbreaks.
Regional Insights
Based on Region, North America have emerged as the dominating region in the Global Next-Generation In-vitr%lI%Diagnostics Market in 2023. This can be attributed t%lI%several key factors. The region boasts a robust and advanced healthcare infrastructure, facilitating the seamless adoption and integration of innovative diagnostic technologies. North America is home t%lI%key market players wh%lI%are at the forefront of driving advancements in diagnostics. These players bring extensive expertise and resources t%lI%propel the market forward. Ongoing investments in research and development within the biotechnology and healthcare sectors further contribute t%lI%the region's leadership in next-generation in-vitr%lI%diagnostics. There is a growing patient awareness about the benefits of early diagnosis and personalized medicine, which is fueling the demand for advanced diagnostic solutions in this region. Collectively, these factors position North America as a frontrunner in the global market, setting the stage for continued growth and advancements in next-generation in-vitr%lI%diagnostics.
Key Market Players
- Therm%lI%Fisher Scientific Inc.
- Becton, Dickinson, and Company
- Qiagen GmbH
- Illumina Inc.
- Beckman Coulter, Inc.
- Invivoscribe, Inc.
- Sysmex Corporation
- bioMйrieux SA
- VWR International, LLC.
- Danaher Corporation
In this report, the Global Next-Generation In-vitr%lI%Diagnostics Market has been segmented int%lI%the following categories, in addition t%lI%the industry trends which have als%lI%been detailed below:
- Next-Generation In-vitr%lI%Diagnostics Market, By Type:
%lI%POC Testing
%lI%Molecular Diagnostics
%lI%Others
- Next-Generation In-vitr%lI%Diagnostics Market, By Product:
%lI%Instruments
%lI%Software
- Next-Generation In-vitr%lI%Diagnostics Market, By Application:
%lI%Infectious Diseases
%lI%Diabetes
%lI%Cardiology
%lI%Others
- Next-Generation In-vitr%lI%Diagnostics Market, By End User:
%lI%Diagnostic Laboratories
%lI%Academic And Research Institutions
%lI%Others
- Next-Generation In-vitr%lI%Diagnostics Market, By Region:
%lI%United States
%lI%Canada
%lI%Mexico
%lI%Europe
%lI%France
%lI%United Kingdom
%lI%Italy
%lI%Germany
%lI%Spain
%lI%Asia Pacific
%lI%China
%lI%India
%lI%Japan
%lI%Australia
%lI%South Korea
%lI%South America
%lI%Brazil
%lI%Argentina
%lI%Colombia
%lI%Middle East & Africa
%lI%South Africa
%lI%Saudi Arabia
%lI%UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation In-vitr%lI%Diagnostics Market.
Available Customizations:
Global Next-Generation In-vitr%lI%Diagnostics Market report with the given market data, TechSci Research offers customizations according t%lI%a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up t%lI%five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Core Laboratory Diagnostics, POC Testing, Molecular Diagnostics, Others)
5.2.2. By Product (Consumables, Instruments, Software)
5.2.3. By Application (Oncology/Cancer, Infectious Diseases, Diabetes, Cardiology, Others)
5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic and Research Institutions, Others)
5.2.5. By Region
5.2.6. By Company (2023)
5.3. Market Map
6. NORTH AMERICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Product
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Next-Generation In-vitro Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Product
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada Next-Generation In-vitro Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Product
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico Next-Generation In-vitro Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Product
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. EUROPE NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Next-Generation In-vitro Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. Germany Next-Generation In-vitro Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom Next-Generation In-vitro Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy Next-Generation In-vitro Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Product
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain Next-Generation In-vitro Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Product
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. ASIA PACIFIC NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. India Next-Generation In-vitro Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. Japan Next-Generation In-vitro Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. South Korea Next-Generation In-vitro Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. Australia Next-Generation In-vitro Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. South Korea Next-Generation In-vitro Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. SOUTH AMERICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Next-Generation In-vitro Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. Colombia Next-Generation In-vitro Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. Argentina Next-Generation In-vitro Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Next-Generation In-vitro Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Next-Generation In-vitro Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. UAE Next-Generation In-vitro Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Thermo Fisher Scientific Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Becton, Dickinson, and Company
15.3. Qiagen GmbH
15.4. Illumina Inc.
15.5. Beckman Coulter, Inc.
15.6. Invivoscribe, Inc.
15.7. Sysmex Corporation
15.8. bioMйrieux SA
15.9. VWR International, LLC.
15.10. Danaher Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Core Laboratory Diagnostics, POC Testing, Molecular Diagnostics, Others)
5.2.2. By Product (Consumables, Instruments, Software)
5.2.3. By Application (Oncology/Cancer, Infectious Diseases, Diabetes, Cardiology, Others)
5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic and Research Institutions, Others)
5.2.5. By Region
5.2.6. By Company (2023)
5.3. Market Map
6. NORTH AMERICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Product
6.2.3. By Application
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Next-Generation In-vitro Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Product
6.3.1.2.3. By Application
6.3.1.2.4. By End User
6.3.2. Canada Next-Generation In-vitro Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Product
6.3.2.2.3. By Application
6.3.2.2.4. By End User
6.3.3. Mexico Next-Generation In-vitro Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Product
6.3.3.2.3. By Application
6.3.3.2.4. By End User
7. EUROPE NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Application
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Next-Generation In-vitro Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Application
7.3.1.2.4. By End User
7.3.2. Germany Next-Generation In-vitro Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Application
7.3.2.2.4. By End User
7.3.3. United Kingdom Next-Generation In-vitro Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Application
7.3.3.2.4. By End User
7.3.4. Italy Next-Generation In-vitro Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Product
7.3.4.2.3. By Application
7.3.4.2.4. By End User
7.3.5. Spain Next-Generation In-vitro Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Product
7.3.5.2.3. By Application
7.3.5.2.4. By End User
8. ASIA PACIFIC NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Application
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. India Next-Generation In-vitro Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Application
8.3.1.2.4. By End User
8.3.2. Japan Next-Generation In-vitro Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Application
8.3.2.2.4. By End User
8.3.3. South Korea Next-Generation In-vitro Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Application
8.3.3.2.4. By End User
8.3.4. Australia Next-Generation In-vitro Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Application
8.3.4.2.4. By End User
8.3.5. South Korea Next-Generation In-vitro Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Application
8.3.5.2.4. By End User
9. SOUTH AMERICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Application
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Next-Generation In-vitro Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Application
9.3.1.2.4. By End User
9.3.2. Colombia Next-Generation In-vitro Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Application
9.3.2.2.4. By End User
9.3.3. Argentina Next-Generation In-vitro Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Application
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Application
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Next-Generation In-vitro Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Application
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Next-Generation In-vitro Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Application
10.3.2.2.4. By End User
10.3.3. UAE Next-Generation In-vitro Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product
10.3.3.2.3. By Application
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL NEXT-GENERATION IN-VITRO DIAGNOSTICS MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Thermo Fisher Scientific Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Becton, Dickinson, and Company
15.3. Qiagen GmbH
15.4. Illumina Inc.
15.5. Beckman Coulter, Inc.
15.6. Invivoscribe, Inc.
15.7. Sysmex Corporation
15.8. bioMйrieux SA
15.9. VWR International, LLC.
15.10. Danaher Corporation
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
